Clinical application of liquid biopsies to detect somatic  BRCA1/2  mutations and guide potential therapeutic intervention for patients with metastatic breast cancer

Neelima Vidula; Leif W. Ellisen; Aditya Bardia

doi:10.18632/oncotarget.27863

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer

Neelima Vidula _, Leif W. Ellisen and Aditya Bardia

PDF | Full Text | How to cite

Oncotarget. 2021; 12:63-65. https://doi.org/10.18632/oncotarget.27863

Metrics: PDF 1113 views | Full Text 2164 views | ?

Abstract

Neelima Vidula1, Leif W. Ellisen1 and Aditya Bardia1

1 Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Correspondence to:

Neelima Vidula,

email:

[email protected]

Keywords: cell-free DNA; BRCA1/2; PARP inhibitor; metastatic breast cancer; plasma based genotyping

Received: November 19, 2020 Accepted: December 22, 2020 Published: January 19, 2021

Copyright: © 2021 Vidula et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Plasma based genotyping via cell-free DNA may identify actionable mutations for potential therapeutic intervention in patients with advanced malignancies including breast cancer. In this article, we discuss recent studies using cell-free DNA testing to identify and classify somatic BRCA1/2 mutations in metastatic breast cancer, and potential future applications for the treatment of metastatic breast cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27863

Publication Alerts

Research Perspectives:

Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer

Abstract